Iron Binding Capacity
Iron is transported in plasma complexed to transferrin, which is synthesized in the liver. Each molecule of transferrin has two iron-binding sites, yielding an iron-binding capacity of 1.47 mg/g. Iron-binding capacity, also known as total iron-binding capacity (TIBC), is usually ordered in conjunction with serum iron levels to evaluate iron deficiency in related anemias, hemochromatosis, and other iron deficiency related disorders. TIBC is calculated from transferrin levels measured immunologically.
Decreased TIBC is seen in certain anemias, hemochromatosis, sideroblastic anemia, liver diseases in which protein synthesis is impaired, nephrotic syndrome, thalassemia, and certain cancers. Increased TIBC levels are seen in iron deficiency anemia, infections, liver disorders such as viral hepatitis, pregnancy, and contraceptive use. In addition to TIBC, transferrin percent saturation is also used for evaluation of iron metabolism. Transferrin percent saturation is calculated from the serum iron (mcg/dL) and the total iron-binding capacity (mcg/dL). Increased percent transferrin saturation with iron is seen in iron overload (iron poisoning, hemolytic anemia, sideroblastic anemia, thalassemia, hemochromatosis, pyridoxine deficiency, and aplastic anemia). Decreased percent transferrin saturation with iron is seen in iron deficiency (usually saturation <16%). Transferrin levels can also be used to assess nutritional status.
- Diagnostic evaluation varies in disorders of iron metabolism
- Diagnosis of hemochromatosis
- As an aid in diagnosis of iron deficiency anemia Note: TIBC is increased in iron deficiency and decreased in anemia of chronic disorders, chronic inflammation and some malignancies.
Increased in:
- Iron deficiency anemia
- Certain liver disorders
- Late pregnancy
- Infancy, acute hepatitis
- Oral contraceptives
Decreased in:
- Hemochromatosis
- Nephrotic syndrome
- Starvation/malnutrition
- Cancer
- Thalassemia
- Hyperthyroidism
- Some chronic diseases including infections, inflammatory disorders, chronic renal disease and others
- Chronic liver disease
| Group | mg/dL | mmol/L |
| Infant | 100–400 | 17.9–71.6 |
| Adults | 250–425 | 44.8–76.1 |
Serum (SST) or Plasma Heparin (Green).
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14 days
- Frozen: 28 days
Separate serum of Plasma within 45 minutes of collection.
- Am J Clin Nutr. 2011 May;93(5):975-83. PMID: 21411619]
- Clin Chem Lab Med. 2002 Oct;40(10):1014-8. [PMID: 12476940]
- Clin Chem. 2002 Sep;48(9):1565-70. [PMID: 12194935]
- Curr Med Chem. 2005;12:2683. [PMID: 16305465]
- Clin Chem. 2003 Jan;49(1):175-8. [PMID: 12507977]
- Kidney Int Suppl. 2006;101:S4. [PMID: 16830699]
- Jacobs DS, DeMott WR. Laboratory Test Handbook. 5. Hudson, OH. Lexi-Comp, Inc (2001).